The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs
2025/11/18 | Value in Health
ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees
2025/11/18 | ISPOR
Putting Patients at the Center of Real-World Evidence in European Decision Making - Inside the Third ISPOR Europe Plenary
2025/11/12 | The Evidence Base
Daily Round-Ups: Day 3 of ISPOR Europe
2025/11/12 | The Evidence Base
Pragmatic Trials and the Future of Clinical Evidence - Inside the Second ISPOR Europe Plenary
2025/11/11 | The Evidence Base
Daily Round-Ups: Day 2 of ISPOR Europe
2025/11/11 | The Evidence Base
Rethinking Patient Engagement in Healthcare Investments - Inside the First ISPOR Europe Plenary
2025/11/10 | The Evidence Base
Daily Round-Ups: Day 1 of ISPOR Europe
2025/11/10 | The Evidence Base
ISPOR Institute for Healthcare Transformation Announced at ISPOR Europe
2025/11/10 | ISPOR
What’s Next for HEOR? Rob Abbott reflects on the road to ISPOR Europe 2025
2025/11/04 | The Evidence Base
Is AI redefining evidence generation or just speeding up what we already do?
2025/10/30 | The Evidence Base
How can health economics take a whole health perspective?
2025/10/30 | The Evidence Base
How Can Real-World Evidence Move From Validation to Implementation?
2025/10/30 | The Evidence Base
Are We Ready for True Harmonization Across Payers, Regulators, and Patients?
2025/10/30 | The Evidence Base
Will the EU HTA Regulation Deliver Harmonization or Create New Complexity?
2025/10/30 | The Evidence Base
Can Patient-Centered Collaboration Move From Aspiration to Action in Evidence Generation and Decision Making?
2025/10/30 | The Evidence Base
Preview of the ISPOR Europe 2025 Plenary Sessions
2025/10/24 | The Evidence Base
ISPOR Europe 2025 Plenaries and Speakers Announced
2025/10/14 | ISPOR
Trends of Lipid-Lowering Drug Utilization, Treatment Intensity and LDL-C Target Attainment in Adults With Diabetes and Nondialysis Chronic Kidney Disease in Hong Kong
2025/10/09 | The Lancet Regional Health Asia Pacific
The Effect of Disease-Modifying Therapies on Brain Volume Loss and Disability Accumulation in Multiple Sclerosis
2025/10/09 | The Lancet Regional Health Europe
- 1
- 2 (current)
- 3
- 4
- 5
Subscribe to the HEOR News Desk
SubscribeAlready have an ISPOR Profile? Click here to manage your subscriptions.